Diamyd Medical announced it has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign.
More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd or placebo...
The California based bio-tech company XOMA announced that the U.S. Patent and Trademark Office has issued two new patents to XOMA as part of the company's expanding intellectual property portfolio around its XOMA 052 antibody to interleukin-1 beta (IL-1 beta)...
Voxiva Inc. and PositiveID Corporation, announced that they are integrating PositiveID's wireless iglucose system with Voxiva's care4life diabetes management program.
This will create an innovative, end-to-end wireless diabetes management solution, which the companies will showcase together at the mHealth Summit in Washington, DC on November 8-10...
The school wouldn’t allow Thad to keep his tester kit with him in the classroom. It had to remain in the office, where he couldn’t even get to it when he needed it...
A new service has been launched on the Diabetes UK website to help people with diabetes get involved in research.
By participating in a clinical study or trial, volunteers can play an important part in helping to prevent diabetes, develop new and better treatments, or even one day in finding a cure...
Bristol-Myers Squibb Company and AstraZeneca announced FDA approval of KOMBIGLYZE™ XR, the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR offers...